FINWIRES · TerminalLIVE
FINWIRES

Dollar General Posts 'Solid' Q1, Truist Says

By

Dollar General (DG) posted a "solid" Q1 performance, including a 2.0% growth in comparable sales, Truist said in a note Tuesday.

The report said the firm is benefitting among others from trade-in activity by higher-income consumers, incremental sales from delivery business, and the comparable lift from remodels, while lower-income consumers remain under pressure.

Truist analysts said they are "modestly" raising their 2026/2027 EPS estimates, partly from a lower tax rate.

"We think DG is "interesting" at current levels, but Walmart (WMT, Buy) competition + economic pressures on their core customer keep us cautious," the note said.

Truist raised its price target to $114 from $109 while maintaining its hold rating.

Price: $108.06, Change: $-1.88, Percent Change: -1.71%

Related Articles

Wire

Starwood Property Trust Shares Rise After UBS Upgrade

Starwood Property Trust (STWD) shares rose 1.8% in Tuesday trading after UBS upgraded the stock to buy from neutral and raised the price target to $20 from $19.50.Trading volume stood at 2.5 million shares, compared with a daily average of about 3.1 million.Price: $17.08, Change: $+0.28, Percent Change: +1.67%

$STWD
Wire

Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

Celcuity (CELC) said Tuesday that detailed results from the Phase 3 Viktoria-1 trial showed its investigational breast cancer treatment gedatolisib outperformed Novartis' (NVS) alpelisib plus fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer.Celcuity said the gedatolisib plus fulvestrant and palbociclib, or gedatolisib-triplet reduced the risk of disease progression or death by 50% compared with alpelisib plus fulvestrant, and nearly doubled median progression-free survival to 11.1 months from 5.6 months, while gedatolisib plus fulvestrant, or gedatolisib-doublet extended progression-free survival to 11.3 months, with objective response rates of 48.9% and 35.7%, respectively.The gedatolisib triplet and doublet regimens were generally well tolerated, with mostly low-grade treatment-related adverse events, while overall survival data, a key secondary endpoint, showed promising trends but remain immature. Celcuity plans to submit the data to the US Food and Drug Administration as a supplemental new drug application.Shares of Celcuity were down more than 25% in Tuesday trading.Price: $91.65, Change: $-31.31, Percent Change: -25.46%

$CELC$NVS
Wire

Perplexity AI Building Workload Distribution Platform to Manage Computing Costs, CEO Says

Perplexity AI is building a software platform to distribute artificial intelligence workloads between personal computers and remote cloud servers, Chief Executive Officer Aravind Srinivas said in an interview with Bloomberg Tuesday.The routing system determines in real time whether processing tasks should execute locally or on cloud infrastructure to help lower overall computing expenses, Srinivas said in the interview.The startup introduced the technology at the Computex conference alongside Intel (INTC), though the platform remains hardware agnostic and supports processors from Nvidia (NVDA), Srinivas added.Price: $107.06, Change: $-2.27, Percent Change: -2.08%

$INTC$NVDA